CAS |
124750-99-8 |
Chinese Name |
氯沙坦钾 |
English Name |
Losartan Potassium |
Synonym |
氯沙坦钾;科素亚钾盐;氯沙坦钾盐;洛沙坦钾; |
Unit |
Bottle |
Purity |
HPLC≥98% |
Molecular Formula |
C22H22CIKN6O |
Molecular Weight |
461 |
Appearance |
White to off-white solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO≥ 25mg/ml |
MDL |
MFCD02092704 |
EC |
EINECS 200-287-4 |
InChIKey |
OXCMYAYHXIHQOA-UHFFFAOYSA-N |
InChI |
InChI=1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1 |
PubChem CID |
11751549 |
SMILES |
OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=N[N-]N=N4)C=C2.[K+] |
Description |
It is an angiotensin II receptor type 1 (AT1) antagonist. |
Target Point |
Angiotensin Receptor |
Passage |
GPCR & G Protein |
Data Literature Source |
[1]. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12.
[2]. Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014.
[3]. Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31.
[4]. Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21.
[5]. Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40. |
Specification |
50mg 100mg 10mM*1mL (in DMSO) |